^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    surovatamig (AZD0486)

    i
    Other names: AZD0486, TNB-486, AZD-0486
    Associations

    News

    Trials
    Company:
    AstraZeneca
    Drug class:
    CD3 agonist, CD19 inhibitor
    Related drugs:
    Associations

    News

    Trials
    9d
    SOUNDTRACK-C1: Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV) (clinicaltrials.gov)
    P3, N=420, Recruiting, AstraZeneca | Not yet recruiting --> Recruiting | Trial completion date: Aug 2033 --> Apr 2032 | Trial primary completion date: Nov 2032 --> Aug 2031
    Enrollment open • Trial completion date • Trial primary completion date
    |
    IGH (Immunoglobulin Heavy Locus)
    |
    surovatamig (AZD0486)
    14d
    SYRUS: AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia (clinicaltrials.gov)
    P1/2, N=236, Recruiting, AstraZeneca | N=163 --> 236
    Enrollment change
    |
    CD19 (CD19 Molecule)
    |
    surovatamig (AZD0486)
    1m
    ASSURO: Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants (clinicaltrials.gov)
    P1, N=48, Recruiting, AstraZeneca
    Trial initiation date
    |
    surovatamig (AZD0486)
    1m
    SOUNDTRACK-D2: AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL (clinicaltrials.gov)
    P3, N=420, Recruiting, AstraZeneca
    Trial initiation date
    |
    doxorubicin hydrochloride • cyclophosphamide • surovatamig (AZD0486)
    1m
    CLEAR-AbKD: A Study to Assess the Effect of Surovatamig in Adult Participants With Antibody-mediated Kidney Disease (clinicaltrials.gov)
    P2, N=43, Recruiting, AstraZeneca
    New P2 trial
    |
    surovatamig (AZD0486)
    1m
    SOUNDTRACK-B: Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL (clinicaltrials.gov)
    P2, N=240, Recruiting, AstraZeneca | N=82 --> 240
    Enrollment change
    |
    CD19 (CD19 Molecule)
    |
    surovatamig (AZD0486)
    2ms
    Soundtrack-E: A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies (clinicaltrials.gov)
    P1/2, N=408, Recruiting, AstraZeneca | N=276 --> 408 | Trial completion date: Feb 2028 --> Jun 2029
    Enrollment change • Trial completion date
    |
    CD19 (CD19 Molecule)
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • Calquence (acalabrutinib) • vincristine • prednisone • surovatamig (AZD0486)
    2ms
    SOUNDTRACK-C1: Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV) (clinicaltrials.gov)
    P3, N=420, Not yet recruiting, AstraZeneca
    New P3 trial
    |
    IGH (Immunoglobulin Heavy Locus)
    |
    surovatamig (AZD0486)
    3ms
    SOUNDTRACK-D2: AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL (clinicaltrials.gov)
    P3, N=420, Recruiting, AstraZeneca
    Trial initiation date
    |
    doxorubicin hydrochloride • cyclophosphamide • surovatamig (AZD0486)
    3ms
    An ALLG international randomised phase III trial of Surovatamig versus radiotherapy with or without Rituximab in limited stage nodal Follicular Lymphoma (ACTRN12626000311358)
    P3, N=168, Not yet recruiting, Australasian Leukaemia and Lymphoma Group
    New P3 trial
    |
    Rituxan (rituximab) • surovatamig (AZD0486)
    4ms
    D7402C00001: A trial to learn how safe AZD0486 is and how well it works in older or physically weak adults with large B-cell lymphoma when given after R-mini-CHOP (2025-522029-37-00)
    P2/3, N=30, Not yet recruiting, AstraZeneca AB
    New P2/3 trial
    |
    Rituxan (rituximab) • cyclophosphamide • vincristine • Truxima (rituximab-abbs) • Actemra IV (tocilizumab) • Neulasta (pegfilgrastim) • surovatamig (AZD0486)
    4ms
    D740AC00001: A study to investigate safety, tolerability, pharmacokinetics, and pharmacodynamics of surovatamig in adult participants with rheumatoid arthritis or systemic lupus erythematosus. (2025-522273-10-00)
    P1, N=15, Not yet recruiting, AstraZeneca AB
    New P1 trial
    |
    surovatamig (AZD0486)